NASDAQ · Biotechnology

Travere Therapeutics, Inc. (TVTX) Stock

$52.13 +0.16% NASDAQ: TVTX Healthcare

Valuation

MetricValue
Price$52.13
Market Cap$4.85B
P/E Ratio-133.31
P/B Ratio228.69
P/S Ratio9.43
EPS (TTM)$-0.50
52-Week High$68.73
52-Week Low$22.59
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-55.79%
ROA-5.44%
ROCE-6.25%
Gross Margin55.95%
Operating Margin-29.02%
Net Margin-7.35%
Debt/Equity25.16
Current Ratio3.13

Annual Financials (USD)

Metric20212022202320242025
Revenue$132.0M$109.0M$145.0M$233.0M$491.0M
Operating Profit$-199.0M$-320.0M$-388.0M$-324.0M$-63.0M
Net Profit$-180.0M$-278.0M$-111.0M$-322.0M$-26.0M
EPS$-3.01$-4.37$-1.50$-4.08$-0.56
Op Margin-151.3%-292.2%-267.2%-138.9%-12.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$777.0M$673.0M$789.0M$594.0M$605.0M
Total Liabilities$475.0M$630.0M$588.0M$535.0M$490.0M
Cash$166.0M$62.0M$58.0M$59.0M$93.0M
Borrowings$262.0M$407.0M$405.0M$402.0M$329.0M

Latest News

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire · Jul 10, 2026 Travere Therapeutics Accounting Chief Sandra Calvin to Retire in 2027 MT Newswires · Jul 10, 2026 Travere Therapeutics Shows Favorable Setup With Filspari as Growth Asset, Wedbush Says MT Newswires · Jun 22, 2026 Wedbush Adjusts Price Target on Travere Therapeutics to $61 From $55, Maintains Outperform Rating MT Newswires · Jun 22, 2026 Travere Therapeutics Chief Research Officer William Rote to Retire MT Newswires · Jun 16, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-15.0M$-186.0M$-280.0M$-237.0M$38.0M
Investing Cash Flow$-162.0M$-61.0M$14.0M$-2.0M$-30.0M
Financing Cash Flow$7.0M$-7.0M$28.0M$5.0M$-2.0M
Net Cash Flow$81.0M$-104.0M$-4.0M$0$35.0M
Free Cash Flow$-39.0M$-215.0M$-322.0M$-339.0M$-20.0M

Valuation & Return Ratios

MetricValue
PEG Ratio1.16
EV / EBITDA3936.41
FCF Yield0.92%
Quick Ratio3.99
Interest Coverage-4.27
Return 1Y208.65%
Return 3Y360.04%
Return 5Y218.17%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
MAZEMaze Therapeutics, Inc. $27.11 +4.75% -9.65 $1.50B 0.00%
MLYSMineralys Therapeutics, Inc. $23.37 +4.42% -6.04 $2.06B 0.00%
PHARPharming Group N.V. $9.68 -1.22% 66.30 $685.13M 0.00%
PROKProKidney Corp. $1.74 +4.82% -2.75 $585.08M 0.00%

About Travere Therapeutics, Inc.

Travere Therapeutics, Inc. (TVTX) stock trades at $52.13 with a market capitalization of $4.85B. The stock is valued at a price-to-earnings (P/E) ratio of -133.31, price-to-book of 228.69, price-to-sales of 9.43. Over the past 52 weeks the stock has ranged between $22.59 and $68.73, and currently trades 24.2% below its 52-week high.

On profitability, Travere Therapeutics, Inc. generates a return on equity (ROE) of -55.79%, return on capital employed of -6.25%, an operating margin of -29.02%, a net profit margin of -7.35%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides